Exosome Therapy for Hair Loss: A Real 3-Month Result and an Honest Look at the Evidence

Hair loss marketing in Pakistan is full of dramatic claims and borrowed photographs. We would rather start with what we can actually document: one of our own patients, photographed in our own clinic, before treatment and again at three months.

We also have to be straight about the limits of these particular photographs. The baseline was taken from above with the head lowered and the hair dry. The follow-ups were taken from the front with the hair damp. Different angle, different lighting, different hair condition, so this is documentation of one patient over time rather than a controlled comparison. Damp hair in particular separates into strands and lets more scalp show through, which works against the follow-up images rather than for them.

Read honestly, the three-month change here is modest: the frontal zone holds more hair and the hairline edge is less ragged, but nobody should look at this and expect a transformation. That is the realistic shape of a three-month response to regenerative scalp therapy, and we would rather publish a modest real result than a spectacular borrowed one.

This case is also the reason our photography protocol changed. Standardised images at baseline, same angle, same lighting, same dry styled hair, are now taken at the first visit for every hair patient, because without them you end up arguing about a memory instead of reading a result.

Exosomes are extracellular vesicles released by cells to communicate with other cells. They carry growth factors, signalling proteins, lipids, and genetic material, and they are best understood as messengers rather than as a drug or a cell transplant.

In hair restoration, an exosome preparation is applied to the scalp and delivered into the skin, most often immediately after microneedling or by fine mesotherapy injections into the affected areas. The intention is to influence the environment around the hair follicle: signalling that supports the growth phase of the hair cycle, improves the local blood supply, and reduces the inflammation around miniaturising follicles.

A session takes roughly thirty to forty-five minutes including numbing. Patients typically describe pressure and pinpricks rather than significant pain, and most return to normal routine the same day with a mildly tender scalp overnight.

This is where honesty matters more than enthusiasm. Published clinical evidence for exosome therapy in hair loss is early: mostly small studies, varied preparations, short follow-up, and inconsistent outcome measures. A 2025 systematic review of clinical evidence across alopecia types found encouraging signals for hair density and thickness while explicitly noting the heterogeneity of products and the need for larger controlled trials.

Regulatory status matters as well. The US FDA has issued a public safety notification stating that exosome products are not FDA-approved and warning patients about unapproved regenerative claims. That does not make the treatment useless, but it does mean any clinic presenting exosome therapy as a proven cure is going beyond what the current literature supports.

Our position is straightforward: exosome therapy is a reasonable adjunct in selected patients, and it is offered as part of a plan alongside established treatments rather than as a replacement for them.

The best responders are patients with early to moderate androgenetic alopecia who still have visible miniaturised hairs in the thinning zone. Where follicles are miniaturising but still present, there is something to stimulate. Where the scalp has been smooth and shiny for years, the follicles are gone and no injectable will bring them back.

Patients recovering from telogen effluvium, the diffuse shedding that follows illness, surgery, severe stress, rapid weight loss, or childbirth, often do well because the underlying follicles are healthy and the problem is a disrupted cycle.

It is also used as supportive therapy around hair transplant surgery, and in patients who have plateaued on medical therapy alone. It is not appropriate as the primary treatment for scarring alopecias, which need a medical diagnosis and anti-inflammatory management first.

Hair loss is frequently a symptom rather than a diagnosis, and treating the scalp while ignoring the cause wastes both money and months. Before starting a course, we assess for the common reversible contributors: iron deficiency using ferritin rather than haemoglobin alone, thyroid dysfunction, vitamin D deficiency, and, in women, the hormonal patterns associated with polycystic ovary syndrome.

Iron deficiency in particular is common among women in Pakistan and is one of the most frequently missed causes of persistent hair shedding. Correcting ferritin can change the trajectory of hair loss on its own, and it also improves the response to anything done procedurally.

If a treatable medical cause is found, it is corrected in parallel. Procedures work better on a scalp that is not fighting a deficiency.

A typical course is three to four sessions spaced about four weeks apart, followed by reassessment and, in responders, maintenance sessions a few times a year.

Month one usually shows nothing visible, and some patients notice a brief increase in shedding as follicles synchronise into a new cycle. This is expected and is not a sign the treatment has failed. Month two to three is where reduced shedding and short new hairs typically appear, which is the stage the photographs above were taken at, and it is usually a subtle change rather than an obvious one. Month four to six is where density change becomes visible to other people rather than only under clinic lighting.

Hair grows at roughly one centimetre a month. Any protocol promising visible density in two weeks is describing something other than hair biology.

It will not regrow hair on a completely bald scalp where follicles are no longer present. It will not stop androgenetic alopecia permanently, because the underlying hormonal sensitivity of the follicles remains, which is why maintenance is part of the plan. It is also not a like-for-like substitute for medical therapy such as topical minoxidil or, in appropriate male patients under medical supervision, oral treatment.

Where hair loss is advanced and the donor area is good, a hair transplant remains the definitive option, and regenerative therapy is best used to support the surrounding native hair rather than to avoid a decision that has already become obvious.

At Ayra Aesthetics & Dental Lounge, hair consultations begin with an assessment of the pattern and stage of loss, relevant blood work, and a written plan that states which parts of the plan are established therapy and which are adjunctive.

Standardised photography at baseline, at each review, and at the end of a course, taken in the same room, at the same distance, in the same lighting, with the hair parted the same way. Without that discipline, comparisons are meaningless and both patient and clinician end up arguing about a memory.

Every published photograph carries written consent, and we do not publish images of patients who prefer to stay private. We are also planning short educational videos from our dermatology and aesthetics team so that treatment explanations come directly from the doctors performing them.

If you are dealing with hair fall and want an assessment rather than a package, book a consultation or message us on WhatsApp and we will tell you honestly whether you are the kind of patient this treatment helps.